| Efficacy of tixagevimab-cilgavimab in preventing SARS-CoV-2 for patients with B-cell malignancies JA Davis, K Granger, K Roubal, D Smith, KJ Gaffney, M McGann, ... Blood 141 (2), 200-203, 2023 | 51 | 2023 |
| Real-world experience of patients with multiple myeloma receiving ide-cel after a prior BCMA-targeted therapy CJ Ferreri, MAT Hildebrandt, H Hashmi, LO Shune, JP McGuirk, ... Blood Cancer Journal 13 (1), 117, 2023 | 46 | 2023 |
| Efficacy and safety of CD34+ stem cell boost for delayed hematopoietic recovery after BCMA directed CAR T-cell therapy JA Davis, DW Sborov, W Wesson, K Julian, AO Abdallah, JP McGuirk, ... Transplantation and Cellular Therapy 29 (9), 567-571, 2023 | 26 | 2023 |
| Idecabtagene vicleucel versus ciltacabtagene autoleucel: a Sophie’s choice for patients with relapsed refractory multiple myeloma J Davis, M McGann, A Shockley, H Hashmi Expert Review of Hematology 15 (6), 473-475, 2022 | 18 | 2022 |
| Safety and Efficacy of Teclistamab in Patients with Relapsed/Refractory Multiple Myeloma: A Real-World Experience D Dima, JA Davis, N Ahmed, X Jia, A Sannareddy, H Shaikh, L Shune, ... Transplantation and cellular therapy 30 (3), 308. e1-308. e13, 2024 | 16 | 2024 |
| Idecabtagene Vicleucel (Ide-cel) Chimeric Antigen Receptor (CAR) T-Cell Therapy in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) Who Have Received a Prior BCMA … CJ Ferreri, MAT Hildebrandt, H Hashmi, LO Shune, JP McGuirk, ... Blood 140 (Supplement 1), 1856-1858, 2022 | 15 | 2022 |
| Development and validation of a prediction model of outcome after B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in relapsed/refractory multiple … N Gagelmann, D Dima, M Merz, H Hashmi, N Ahmed, N Tovar, ... Journal of Clinical Oncology 42 (14), 1665-1675, 2024 | 14 | 2024 |
| Impact of Frailty on Outcomes After CAR T-cell Therapy for Patients with Relapsed/Refractory Multiple Myeloma JA Davis, D Dima, N Ahmed, S DeJarnette, J McGuirk, X Jia, S Raza, ... Transplantation and Cellular Therapy, 2023 | 14 | 2023 |
| Stem Cell Mobilization for Multiple Myeloma Patients Receiving Daratumumab-Based Induction Therapy: A Real-World Experience A Thurlapati, K Roubal, JA Davis, SZ Shah, D Smith, M McGann, ... Transplantation and Cellular Therapy 29 (5), 340. e1-340. e4, 2023 | 14 | 2023 |
| Real-World Experience and Optimization of Outpatient Chimeric Antigen Receptor T Cell Therapy M McGann, JA Davis, KJ Gaffney, D Smith, K Edwards, BT Hess, ... Transplantation and Cellular Therapy, Official Publication of the American …, 2022 | 14 | 2022 |
| Idecabtagene vicleucel chimeric antigen receptor T-cell therapy for relapsed/refractory multiple myeloma with renal impairment S Sidana, LC Peres, H Hashmi, H Hosoya, C Ferreri, J Khouri, D Dima, ... Haematologica 109 (3), 777, 2024 | 13 | 2024 |
| Real-World Safety and Efficacy of Teclistamab for Patients with Heavily Pretreated Relapsed-Refractory Multiple Myeloma D Dima, JA Davis, N Ahmed, A Sannareddy, H Shaikh, Z Mahmoudjafari, ... Blood 142, 91, 2023 | 13 | 2023 |
| Racial and Ethnic Differences in Clinical Outcomes Among Multiple Myeloma Patients Treated with CAR T Therapy LC Peres, LB Oswald, C Dillard, G De Avila, T Nishihori, BJ Blue, ... Blood 140 (Supplement 1), 623-625, 2022 | 11 | 2022 |
| The emergence of b-cell maturation antigen (BCMA) targeting immunotherapy in multiple myeloma JA Davis, A Shockley, H Hashmi Journal of Oncology Pharmacy Practice 28 (4), 960-968, 2022 | 11 | 2022 |
| Newly approved anti-CD19 monoclonal antibodies for the treatment of relapsed or refractory diffuse large B-cell lymphoma JA Davis, A Shockley, AE Glode Journal of Oncology Pharmacy Practice 28 (3), 686-690, 2022 | 10 | 2022 |
| Idecabtagene Vicleucel Chimeric Antigen Receptor T-Cell Therapy for Relapsed/Refractory Multiple Myeloma with Renal Insufficiency: Real World Experience S Sidana, LC Peres, H Hashmi, H Hosoya, CJ Ferreri, S Atrash, J Khouri, ... Blood 140 (Supplement 1), 10377-10379, 2022 | 9 | 2022 |
| Factors associated with refractoriness or early progression after idecabtagene vicleucel in patients with relapsed/refractory multiple myeloma: US Myeloma Immunotherapy … H Hashmi, DK Hansen, LC Peres, OC Puglianini, C Freeman, G De Avila, ... Haematologica 109 (5), 1514, 2024 | 8 | 2024 |
| Toxicity and Efficacy Outcomes of Teclistamab in Patients with Relapsed-Refractory Multiple Myeloma (RRMM) Above the Age of 70 Years: A Multicenter Study D Dima, A Sannareddy, N Ahmed, JA Davis, H Shaikh, Z Mahmoudjafari, ... Blood 142, 3330, 2023 | 8 | 2023 |
| Newly approved and forthcoming T-cell-redirecting bispecific antibodies for the treatment of relapsed/refractory multiple myeloma K Granger, KJ Gaffney, JA Davis Journal of Oncology Pharmacy Practice 29 (3), 722-726, 2023 | 8 | 2023 |
| Chimeric antigen receptor T-cell (CAR T-cell) therapy for primary and secondary central nervous system lymphoma: a systematic review of literature N Asghar, A Masood, A Dhaliwal, S Khurana, J Davis, H Hashmi, ... Clinical Lymphoma Myeloma and Leukemia 23 (1), 15-21, 2023 | 8 | 2023 |
Nausheen AhmedUniversity of Kansas在 kumc.edu 的电子邮件经过验证
